Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $58.74B | 13.4x | 1.31 | $548.95 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | $46.60B | 58x | $65.96 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.9% Upside | Upgrade to Pro+ | ||
argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $36.03B | 42.4x | 0.12 | $589.75 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.2% Upside | Upgrade to Pro+ | |
IQVIA Holdings | NYSE | Healthcare | Biotechnology & Medical Research | $26.26B | 19.8x | 6.81 | $149.21 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BeiGene ADS | NASDAQ | Healthcare | Biotechnology & Medical Research | $25.73B | -44.4x | -1.4 | $235.81 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39% Upside | Upgrade to Pro+ | |
BioNTech | NASDAQ | Healthcare | Biotechnology & Medical Research | $23.53B | -31.1x | 0.18 | $98.28 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.7% Upside | Upgrade to Pro+ | |
Summit Therapeutics PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | $18.16B | -59.7x | -1.13 | $23.34 | -5.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.2% Upside | Upgrade to Pro+ | |
Insmed | NASDAQ | Healthcare | Biotechnology & Medical Research | $12.64B | -12.5x | 3.15 | $69.99 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.2% Upside | Upgrade to Pro+ | |
Genmab AS | NASDAQ | Healthcare | Biotechnology & Medical Research | $12.40B | 10.5x | 0.12 | $19.53 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.5% Upside | Upgrade to Pro+ | |
ICON PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | $11.76B | 15.2x | 0.51 | $145.62 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.7% Upside | Upgrade to Pro+ | |
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | $11.06B | 31.2x | 31.43 | $5.22 | -3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | $11.06B | 31.2x | 31.43 | $2.74 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Exelixis | NASDAQ | Healthcare | Biotechnology & Medical Research | $10.15B | 20x | 0.11 | $36.21 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.8% Upside | Upgrade to Pro+ | |
Moderna | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.93B | -2.8x | -0.11 | $25.69 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.5% Upside | Upgrade to Pro+ | |
Ascendis Pharma AS | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.21B | -22.1x | -0.89 | $155.59 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36% Upside | Upgrade to Pro+ | |
Medpace Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.17B | 23x | 0.53 | $301.12 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.2% Upside | Upgrade to Pro+ | |
Qiagen | NYSE | Healthcare | Biotechnology & Medical Research | $8.99B | 106.6x | -1.43 | $41.59 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.2% Upside | Upgrade to Pro+ | |
EXACT Sciences | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.04B | -7.8x | 0.02 | $43.34 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.8% Upside | Upgrade to Pro+ | |
Bio-Techne | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.94B | 50.3x | -1.71 | $50.34 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tempus AI | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.43B | -7.8x | 0.2 | $41.60 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Madrigal Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.90B | -14.3x | 1.58 | $311.31 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.4% Upside | Upgrade to Pro+ | |
Revolution Med | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.66B | -9.9x | -1.53 | $35.87 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Legend Bio | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.03B | -34x | -0.49 | $32.90 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Telix Pharmaceuticals ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.64B | 190.5x | 0.22 | $16.51 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.4% Upside | Upgrade to Pro+ | |
Blueprint Medicines Corp | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.09B | -74.4x | -0.88 | $79.59 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Charles River Laboratories | NYSE | Healthcare | Biotechnology & Medical Research | $5.08B | 520.9x | -4.86 | $103.56 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Verona Pharma ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.97B | -30.5x | 0.14 | $57.85 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36% Upside | Upgrade to Pro+ | |
Nuvalent | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.96B | -17.6x | 0.22 | $69.07 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Krystal Biotech | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.72B | 52.4x | 0.08 | $163.69 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.1% Upside | Upgrade to Pro+ | |
Cytokinetics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.54B | -7.3x | -2.26 | $38.27 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alkermes Plc | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.49B | 12.1x | 3.4 | $27.22 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.6% Upside | Upgrade to Pro+ | |
Ionis Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.48B | -9.2x | 0.52 | $28.25 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
PureTech Health | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.02B | -55.8x | 0.06 | $16.75 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vaxcyte | NASDAQ | Healthcare | Biotechnology & Medical Research | $3.80B | -7.7x | -1.06 | $29.50 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Arcellx | NASDAQ | Healthcare | Biotechnology & Medical Research | $3.38B | -32.3x | 0.84 | $59.53 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Crispr Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $3.21B | -8.6x | 0.07 | $37.40 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Soleno Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $3.16B | -15.6x | 0.21 | $69 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.3% Upside | Upgrade to Pro+ | |
Akero Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.95B | -9.9x | 0.37 | $37.12 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merus | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.90B | -12.5x | 1.15 | $42 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Protagonist Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.83B | 10.3x | 0.02 | $46.08 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47% Upside | Upgrade to Pro+ | |
Scholar Rock | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.80B | -11.3x | 0.53 | $29.56 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Crinetics Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.71B | -7.9x | $29.08 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Alvotech | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.60B | -11.2x | -0.18 | $8.48 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viking Therapeutics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.57B | -22.6x | 2.11 | $22.98 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Immunovant | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.53B | -5.7x | 0.15 | $14.90 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xenon Pharmaceuticals | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.50B | -10.9x | 0.99 | $32.94 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ACADIA | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.43B | 10.6x | 0.02 | $14.60 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Veracyte Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.43B | 97.8x | 0.79 | $31.07 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.1% Upside | Upgrade to Pro+ | |
MoonLake Immunotherapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.29B | -19.1x | 0.12 | $36.23 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Immunitybio Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.23B | -4.4x | -0.12 | $2.61 | -6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |